Pub Date : 2025-11-04DOI: 10.1016/j.clinre.2025.102727
Anthony Buisson , Jérémy Denizot
{"title":"Adherent-invasive E. coli (AIEC) in Crohn’s disease: where are we in 2025? Tribute to Professor Nicolas Barnich","authors":"Anthony Buisson , Jérémy Denizot","doi":"10.1016/j.clinre.2025.102727","DOIUrl":"10.1016/j.clinre.2025.102727","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102727"},"PeriodicalIF":2.4,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-04DOI: 10.1016/j.clinre.2025.102730
Jingxia Yu , Wenhui Xia , Lei Xu , Qianqian Wang , Yuxuan Chen , Shuo Zhang
{"title":"A fishbone hidden for 2 months: Successfully located by endoscopic ultrasound and removed by submucosal tunnel endoscopic resection","authors":"Jingxia Yu , Wenhui Xia , Lei Xu , Qianqian Wang , Yuxuan Chen , Shuo Zhang","doi":"10.1016/j.clinre.2025.102730","DOIUrl":"10.1016/j.clinre.2025.102730","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102730"},"PeriodicalIF":2.4,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.clinre.2025.102728
Aurélien Amiot , Anthony Buisson , Jean Marc Gornet , Mathurin Fumery , Lucine Vuitton , Pascal Juillerat , Arnaud Bourreille , David Laharie , Guillaume Bouguen , GETAID educational committee
The therapeutic arsenal for treating Crohn’s disease has grown rapidly, expanding to include advanced therapies with various modes of action. Over the last two decades, physicians and patients have significantly improved the treatment of Crohn’s disease, setting ambitious goals. In 2024, French clinical guidelines were established through a validated process involving the adaptation of international gastroenterology societies' clinical guidelines and French consensus meetings. The French guidelines aimed to ensure the applicability of new approaches in France, taking into account specific restrictions on drug authorization and reimbursement. This position statement outlines the specificity of the French guidelines compared to other international recommendations.
{"title":"Diagnosis and management of patients with Crohn’s disease. Position paper from the GETAID","authors":"Aurélien Amiot , Anthony Buisson , Jean Marc Gornet , Mathurin Fumery , Lucine Vuitton , Pascal Juillerat , Arnaud Bourreille , David Laharie , Guillaume Bouguen , GETAID educational committee","doi":"10.1016/j.clinre.2025.102728","DOIUrl":"10.1016/j.clinre.2025.102728","url":null,"abstract":"<div><div>The therapeutic arsenal for treating Crohn’s disease has grown rapidly, expanding to include advanced therapies with various modes of action. Over the last two decades, physicians and patients have significantly improved the treatment of Crohn’s disease, setting ambitious goals. In 2024, French clinical guidelines were established through a validated process involving the adaptation of international gastroenterology societies' clinical guidelines and French consensus meetings. The French guidelines aimed to ensure the applicability of new approaches in France, taking into account specific restrictions on drug authorization and reimbursement. This position statement outlines the specificity of the French guidelines compared to other international recommendations.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102728"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-30DOI: 10.1016/j.clinre.2025.102726
M. Uzzan , M. Barrau , X. Roblin
{"title":"Associations of advanced therapies in inflammatory bowel diseases","authors":"M. Uzzan , M. Barrau , X. Roblin","doi":"10.1016/j.clinre.2025.102726","DOIUrl":"10.1016/j.clinre.2025.102726","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102726"},"PeriodicalIF":2.4,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Update on IBD management: What's new in acute severe UC? - Modern management of perianal disease","authors":"David Laharie , Pauline Rivière , Amandine Landemaine , Guillaume Bouguen","doi":"10.1016/j.clinre.2025.102725","DOIUrl":"10.1016/j.clinre.2025.102725","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102725"},"PeriodicalIF":2.4,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-28DOI: 10.1016/j.clinre.2025.102722
Zijin Liu , Yingqi Wang , Jiayi Hong , Fang He , Lijie Hao , Linmin Liu , Huihong Zhai
Background & Aims
Current surveillance strategies for autoimmune gastritis (AIG) lack consensus, and the prognostic role of serum biomarkers remains unclear. This meta-analysis aimed to evaluate the correlation between serum biomarkers and the risks of gastric lesions in AIG patients.
Methods
Studies comparing serum biomarkers in AIG patients with versus without neuroendocrine tumor (NET), gastric polyp (GP), or gastric cancer (GC) were identified by searching PubMed, EMBASE, and Cochrane databases (up to March 2025). Basic studies, meta-analyses, reviews, case reports, or studies not published in English were excluded. Two investigators independently extracted data and quality-assessed using the Newcastle–Ottawa and AHRQ scales. Statistical analysis used Review Manager 5.4 and Stata MP18. Heterogeneity and publication bias were evaluated. Sensitivity analysis was used to manage heterogeneity and assess the stability of the result.
Results
Thirteen studies (10 for NET, 4 for GP, and 1 for GC) were included. Elevated serum gastrin correlated significantly with NET (MD: 519.05, 95% CI: 227.96∼810.13, P = 0.0005, I2=85%) and GP (MD: 70.54, 95% CI: 43.59∼97.49, P < 0.00001, I2=0%; weighted mean: 240.02 pg/ml). With a high heterogeneity in the NET group, we arranged sensitivity analysis and removed two studies that caused heterogeneity, the result consistently showed a statistical difference (MD: 196.62, 95% CI: 76.61∼316.64, P = 0.001, I2=22%; weighted mean: 811.53 pg/ml). Publication bias was found neither in NET (Begg’s test: P = 0.1078, Egger’s test: P = 0.3553) nor in GP (Begg’s test: P = 1.0000, Egger’s test: P = 0.4771) groups. Chromogranin A (CgA), vitamin B12, and parietal cell antibody (PCA) showed no consistent associations. For GC, limited data suggested milder gastrin elevation and higher Helicobacter pylori co-infection rates.
Discussion
Serum gastrin is correlated with NET and GP in AIG patients. The weighted mean serum gastrin level was 811.53 pg/ml in AIG patients with NET, and 240.02 pg/ml in those with GP. Non-enrollment of randomized controlled trials (RCTs), inconsistency in laboratory methods for biomarker detection and diagnostic criteria, and different units of biomarkers may cause limitations of the present study.
{"title":"Do serum biomarkers correlate to the risk of gastric lesions in patients with autoimmune gastritis༟—A systematic review and meta-analysis","authors":"Zijin Liu , Yingqi Wang , Jiayi Hong , Fang He , Lijie Hao , Linmin Liu , Huihong Zhai","doi":"10.1016/j.clinre.2025.102722","DOIUrl":"10.1016/j.clinre.2025.102722","url":null,"abstract":"<div><h3>Background & Aims</h3><div>Current surveillance strategies for autoimmune gastritis (AIG) lack consensus, and the prognostic role of serum biomarkers remains unclear. This meta-analysis aimed to evaluate the correlation between serum biomarkers and the risks of gastric lesions in AIG patients.</div></div><div><h3>Methods</h3><div>Studies comparing serum biomarkers in AIG patients with versus without neuroendocrine tumor (NET), gastric polyp (GP), or gastric cancer (GC) were identified by searching PubMed, EMBASE, and Cochrane databases (up to March 2025). Basic studies, meta-analyses, reviews, case reports, or studies not published in English were excluded. Two investigators independently extracted data and quality-assessed using the Newcastle–Ottawa and AHRQ scales. Statistical analysis used Review Manager 5.4 and Stata MP18. Heterogeneity and publication bias were evaluated. Sensitivity analysis was used to manage heterogeneity and assess the stability of the result.</div></div><div><h3>Results</h3><div>Thirteen studies (10 for NET, 4 for GP, and 1 for GC) were included. Elevated serum gastrin correlated significantly with NET (MD: 519.05, 95% CI: 227.96∼810.13, <em>P</em> = 0.0005, I<sup>2</sup>=85%) and GP (MD: 70.54, 95% CI: 43.59∼97.49, <em>P</em> < 0.00001, I<sup>2</sup>=0%; weighted mean: 240.02 pg/ml). With a high heterogeneity in the NET group, we arranged sensitivity analysis and removed two studies that caused heterogeneity, the result consistently showed a statistical difference (MD: 196.62, 95% CI: 76.61∼316.64, <em>P</em> = 0.001, I<sup>2</sup>=22%; weighted mean: 811.53 pg/ml). Publication bias was found neither in NET (Begg’s test: <em>P</em> = 0.1078, Egger’s test: <em>P</em> = 0.3553) nor in GP (Begg’s test: <em>P</em> = 1.0000, Egger’s test: <em>P</em> = 0.4771) groups. Chromogranin A (CgA), vitamin B12, and parietal cell antibody (PCA) showed no consistent associations. For GC, limited data suggested milder gastrin elevation and higher <em>Helicobacter pylori</em> co-infection rates.</div></div><div><h3>Discussion</h3><div>Serum gastrin is correlated with NET and GP in AIG patients. The weighted mean serum gastrin level was 811.53 pg/ml in AIG patients with NET, and 240.02 pg/ml in those with GP. Non-enrollment of randomized controlled trials (RCTs), inconsistency in laboratory methods for biomarker detection and diagnostic criteria, and different units of biomarkers may cause limitations of the present study.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102722"},"PeriodicalIF":2.4,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To evaluate the prevalence, diagnostic criteria, and predictive factors of cirrhotic cardiomyopathy (CCMP) in pediatric patients with portal hypertension (PHTN), using electrocardiography (ECG), echocardiography, and NT-proBNP levels.
Methods
This cross-sectional study included 54 children with portal hypertension (45 with cirrhosis and 9 without), and 54 age- and sex-matched healthy controls. All participants underwent ECG, echocardiography, and NT-proBNP testing. CCMP was diagnosed based on the Møller-Henriksen criteria. Demographic, clinical, and laboratory variables, including PELD/MELD and Child-Pugh scores, were analyzed. Logistic regression was used to identify predictors of CCMP.
Results
CCMP was identified in 14 cirrhotic patients (31.1 %), with 9 symptomatic and 5 silent cases. No cases were observed among non-cirrhotic patients or controls. The presence of ascites and higher PELD/MELD scores were significantly associated with CCMP. QTc prolongation and reduced ejection fraction were key diagnostic findings. Systolic dysfunction was present in 3 patients, and 4 patients with CCMP died before or shortly after liver transplantation. Multivariate analysis confirmed PELD/MELD score as a significant predictor of CCMP (OR 1.19; 95 % CI 1.038–1.367; p=0.01).
Conclusion
Cirrhotic cardiomyopathy is a prevalent but often silent complication in children with cirrhosis and PHTN. Elevated PELD/MELD scores and the presence of ascites are important predictive factors. Routine cardiac evaluation using ECG, echocardiography, and biomarkers like NT-proBNP is recommended for early detection and risk stratification in this population.
Main Points
Cirrhotic cardiomyopathy (CCMP) is an uncommon yet serious condition in children with liver disease. Current diagnostic criteria require reassessment for pediatric use, particularly considering regional genetic and environmental differences.
目的：通过心电图（ECG）、超声心动图和NT-proBNP水平评估门脉高压（PHTN）患儿肝硬化心肌病（CCMP）的患病率、诊断标准和预测因素。方法：本横断面研究纳入54例门静脉高压症患儿（45例合并肝硬化，9例未合并肝硬化）和54例年龄和性别匹配的健康对照。所有参与者都进行了心电图、超声心动图和NT-proBNP测试。CCMP的诊断基于Møller-Henriksen标准。分析了人口统计学、临床和实验室变量，包括PELD/MELD和Child-Pugh评分。采用Logistic回归确定CCMP的预测因素。结果：14例肝硬化患者（31.1%）发现CCMP，其中9例有症状，5例无症状。在非肝硬化患者或对照组中未观察到病例。腹水的存在和较高的PELD/MELD评分与CCMP显著相关。QTc延长和射血分数降低是主要的诊断结果。3例患者出现收缩功能障碍，4例CCMP患者在肝移植前或移植后不久死亡。多因素分析证实PELD/MELD评分是CCMP的重要预测因子（OR 1.19; 95% CI 1.038 ~ 1.367; p=0.01）。结论：肝硬化心肌病是肝硬化和PHTN患儿的一种常见但通常不明显的并发症。PELD/MELD评分升高和腹水的存在是重要的预测因素。建议使用心电图、超声心动图和NT-proBNP等生物标志物进行常规心脏评估，以便在该人群中进行早期发现和风险分层。要点：肝硬化心肌病（CCMP）是一种罕见但严重的儿童肝脏疾病。目前的诊断标准需要重新评估儿科使用，特别是考虑到区域遗传和环境差异。
{"title":"Cirrhotic cardiomyopathy in children: A comprehensive assessment using ECG, echocardiography, and NT-Pro-BNP","authors":"Ataollahi Maryam , Naghshzan Amir , Haghighat Mahmood , Dehghani Mohsen , Amuzgar Hamid , Kalvandi Gholamreza , Mehdizadegan Nima , Salarian Leila","doi":"10.1016/j.clinre.2025.102721","DOIUrl":"10.1016/j.clinre.2025.102721","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the prevalence, diagnostic criteria, and predictive factors of cirrhotic cardiomyopathy (CCMP) in pediatric patients with portal hypertension (PHTN), using electrocardiography (ECG), echocardiography, and NT-proBNP levels.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 54 children with portal hypertension (45 with cirrhosis and 9 without), and 54 age- and sex-matched healthy controls. All participants underwent ECG, echocardiography, and NT-proBNP testing. CCMP was diagnosed based on the Møller-Henriksen criteria. Demographic, clinical, and laboratory variables, including PELD/MELD and Child-Pugh scores, were analyzed. Logistic regression was used to identify predictors of CCMP.</div></div><div><h3>Results</h3><div>CCMP was identified in 14 cirrhotic patients (31.1 %), with 9 symptomatic and 5 silent cases. No cases were observed among non-cirrhotic patients or controls. The presence of ascites and higher PELD/MELD scores were significantly associated with CCMP. QTc prolongation and reduced ejection fraction were key diagnostic findings. Systolic dysfunction was present in 3 patients, and 4 patients with CCMP died before or shortly after liver transplantation. Multivariate analysis confirmed PELD/MELD score as a significant predictor of CCMP (OR 1.19; 95 % CI 1.038–1.367; p=0.01).</div></div><div><h3>Conclusion</h3><div>Cirrhotic cardiomyopathy is a prevalent but often silent complication in children with cirrhosis and PHTN. Elevated PELD/MELD scores and the presence of ascites are important predictive factors. Routine cardiac evaluation using ECG, echocardiography, and biomarkers like NT-proBNP is recommended for early detection and risk stratification in this population.</div></div><div><h3>Main Points</h3><div>Cirrhotic cardiomyopathy (CCMP) is an uncommon yet serious condition in children with liver disease. Current diagnostic criteria require reassessment for pediatric use, particularly considering regional genetic and environmental differences.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102721"},"PeriodicalIF":2.4,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-23DOI: 10.1016/j.clinre.2025.102715
Jia-Lu Long, Peng Liu
{"title":"Gastrointestinal stromal tumor presenting in the pancreas","authors":"Jia-Lu Long, Peng Liu","doi":"10.1016/j.clinre.2025.102715","DOIUrl":"10.1016/j.clinre.2025.102715","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 10","pages":"Article 102715"},"PeriodicalIF":2.4,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145370174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-13DOI: 10.1016/j.clinre.2025.102714
Saqlain Haider
{"title":"Geography, not genetics: Reframing esophageal cancer mortality in rural populations","authors":"Saqlain Haider","doi":"10.1016/j.clinre.2025.102714","DOIUrl":"10.1016/j.clinre.2025.102714","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102714"},"PeriodicalIF":2.4,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-13DOI: 10.1016/j.clinre.2025.102712
Jérôme Dumortier , Georges-Philippe Pageaux , Audrey Coilly , Claire Francoz , Filomena Conti , Guillaume Lassailly , Sébastien Dharancy , Pauline Houssel-Debry , José Ursic-Bedoya , Hélène Donnadieu , Groupe de recherche français en greffe de foie (GReF2)
{"title":"Screening for alcohol consumption in liver transplant recipients: results of a nationwide French survey","authors":"Jérôme Dumortier , Georges-Philippe Pageaux , Audrey Coilly , Claire Francoz , Filomena Conti , Guillaume Lassailly , Sébastien Dharancy , Pauline Houssel-Debry , José Ursic-Bedoya , Hélène Donnadieu , Groupe de recherche français en greffe de foie (GReF2)","doi":"10.1016/j.clinre.2025.102712","DOIUrl":"10.1016/j.clinre.2025.102712","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 9","pages":"Article 102712"},"PeriodicalIF":2.4,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号